SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Surrozen, Inc./DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$23.84+0.40 (+1.71%)
Close on Oct 19, 2026
- Market cap
- $551.80M
- P/E (TTM)
- –
- Dividend yield
- –
Surrozen statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Surrozen | Industry median |
|---|---|---|
| Market Cap | $280.21M | $166.30M |
| Enterprise Value | $178.17M | $88.19M |
| PS Ratio | 24.34 | 3.65 |
Enterprise value
| Measure | Surrozen | Industry median |
|---|---|---|
| EV / Sales | 15.48 | 2.51 |
Income (trailing twelve months)
| Measure | Surrozen | Industry median |
|---|---|---|
| Revenue | $11.51M | $58.34M |
| Operating Income | -$44.35M | -$21.40M |
| Net Income | -$332.13M | -$22.46M |
| EBITDA | -$44.13M | -$16.91M |
Margins
| Measure | Surrozen | Industry median |
|---|---|---|
| Operating Margin | -385.3% | -44.0% |
| Profit Margin | -2885.3% | -40.2% |
| EBITDA Margin | -383.4% | -30.2% |
| FCF Margin | -303.9% | -9.27% |
Returns
| Measure | Surrozen | Industry median |
|---|---|---|
| Return on Assets (ROA) | -304.3% | -40.9% |
| Return on Capital Employed (ROCE) | -41.6% | -38.1% |
Growth
| Measure | Surrozen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -8.79% | 5.96% |
| Revenue Growth (3Y CAGR) | -34.7% | 2.25% |
Balance sheet
| Measure | Surrozen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $102.04M | $61.43M |
| Net Cash (Debt) | $102.04M | $15.35M |
| Net Cash Per Share | $8.68 | $0.66 |
| Equity (Book Value) | -$218.67M | $49.09M |
| Book Value Per Share | -$18.60 | $1.37 |
| Tangible Book Value | -$218.67M | $23.52M |
| Working Capital | $100.39M | $76.81M |
Financial position
| Measure | Surrozen | Industry median |
|---|---|---|
| Current Ratio | 12.14 | 3.34 |
| Quick Ratio | 11.88 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Surrozen | Industry median |
|---|---|---|
| Operating Cash Flow | -$34.76M | -$12.35M |
| Capital Expenditures | -$222.00K | -$1.08M |
| Free Cash Flow | -$34.98M | -$20.22M |
| FCF Per Share | -$2.98 | -$0.42 |
Efficiency
| Measure | Surrozen | Industry median |
|---|---|---|
| Asset Turnover | 0.11 | 0.39 |
| Revenue Per Employee | $261.61K | $404.87K |
| Profits Per Employee | -$7.55M | -$703.34K |
| Employee Count | 44 | 74 |
Dividends and yields
| Measure | Surrozen | Industry median |
|---|---|---|
| Earnings Yield | -118.5% | -23.3% |
| FCF Yield | -12.5% | -8.72% |
| Buyback Yield | -1.25% | -0.59% |
| Shareholder Yield | -1.25% | 0.00% |
Shares
| Measure | Surrozen | Industry median |
|---|---|---|
| Shares Outstanding | 11,753,600 | 58,127,000 |
| Shares Change (YoY) | 171.0% | 10.9% |
| Shares Change (QoQ) | 2.30% | 0.54% |
| Float | 6,513,470 | 49,136,700 |
| Shares Held by Insiders | 44.6% | 11.6% |
| Shares Held by Institutions | 91.3% | 59.4% |
Scores
| Measure | Surrozen | Industry median |
|---|---|---|
| Altman Z-Score | -6.94 | -0.22 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Surrozen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.